ALT Altimmune, Inc
Price Chart
Executive Summary
Altimmune presented new 48-week data from the IMPACT Phase 2b trial of pemvidutide in MASH at the EASL Congress 2026. The data showed significant reductions in triglycerides (-23.7%), total cholesterol (-15.4%), weight (-7.5%), and blood pressure, alongside previously reported improvements in liver fibrosis biomarkers. The company plans to initiate the PERFORMA Phase 3 trial in the second half of 2026.
Actionable Insight
The broad metabolic data (lipid, weight, BP improvements) differentiates pemvidutide from pure GLP-1 agonists and supports a potential best-in-class profile for MASH. Key catalysts ahead: PERFORMA Phase 3 initiation (H2 2026), RECLAIM AUD topline (Q3 2026), and RESTORE ALD enrollment completion (Q3 2026). Monitor for partnership interest given the balanced glucagon/GLP-1 mechanism.
Key Facts
- Pemvidutide 1.8 mg reduced triglycerides by -23.7% and total cholesterol by -15.4% in MASH patients with elevated baseline lipids.
- Weight loss of 7.5% at 48 weeks with no plateauing; BMI reduction of -3.0 kg/m2; waist circumference reduction of -5.3 cm.
- Systolic blood pressure improved by -4.0 mmHg and diastolic by -2.2 mmHg.
- Previously reported fibrosis endpoints: 32.4% of pemvidutide 1.8 mg patients achieved ≥0.5 reduction in ELF and ≥30% reduction in LSM vs 3.2% for placebo (p<0.0001).
- Discontinuation rate due to AEs was ~1%; safety profile maintained at 48 weeks.
- FDA granted Fast Track and Breakthrough Therapy Designation for pemvidutide in MASH.
- PERFORMA Phase 3 trial expected to initiate in second half of 2026.
- RECLAIM Phase 2 trial in AUD topline data expected Q3 2026; RESTORE trial in ALD enrollment completion expected Q3 2026.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue. Market cap ~$580M. Positive Phase 2b data supports Phase 3 initiation and potential regulatory path.
Risk Factors
- Phase 3 trial may fail to replicate Phase 2b efficacy or safety results.
- Competitive landscape includes Madrigal's Rezdiffra (approved) and other GLP-1/glucagon candidates from Novo Nordisk, Eli Lilly, and others.
- Company has no approved products and will require additional capital to fund Phase 3 and ongoing trials.
- Cardiovascular outcomes data not yet available; MASH patients face high CV mortality risk.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
23d ago
|
Press Release
| $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.70 (−12.05%) |
|
May 27, 2026
24d ago
|
Press Release
| $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.70 (−9.40%) |
|
May 13, 2026
5w ago
|
8-K
| $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.70 (−10.60%) |
|
May 13, 2026
5w ago
|
Press Release
| $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.70 (−10.60%) |
|
May 13, 2026
5w ago
|
Press Release
| $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.70 (−10.60%) |
|
May 6, 2026
6w ago
|
Press Release
| $3.26 $3.08 | ▼ −5.52% | ▼ −6.65% | $2.70 (−17.18%) |
|
Apr 24, 2026
8w ago
|
8-K
| $2.80 $3.02 | ▲ +7.86% | ▲ +7.46% | $2.70 (−3.57%) |
|
Apr 24, 2026
8w ago
|
424B5
| $2.85 $2.60 | ▼ −8.77% | ▼ −9.68% | $2.70 (−5.26%) |
|
Apr 23, 2026
8w ago
|
Press Release
| $2.89 $2.63 | ▲ +9.00% | ▲ +10.47% | $2.70 (+6.57%) |
|
Apr 22, 2026
8w ago
|
424B5
| $2.89 $2.63 | ▼ −9.00% | ▼ −10.47% | $2.70 (−6.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access